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Introduction 
Gaucher disease (GD) is a rare condition caused by an 
inherited, autosomal recessive deficiency of the enzyme 
P-glucocerebrosidase, resulting in an accumulation of 
glucocerebroside in the lysosomes of macrophages and 
monocytes. Three distinct clinical forms are recognized. 
Type 1 (chronic non-neuropathic or ‘adult form’) is 
the most common, and its onset can occur at any age. 
This form is most frequent among Ashkenazy Jews, 
although any race can be affected. It is characterized by 
hepatosplenomegaly, thrombocytopenia and bone lesions, 
and lung involvement is rare (1). Type 2 (acute neuropathic) 
is characterized by severe visceral involvement and an 
intense and early neurological affection, with spasticity, 
bulbar signs and oculomotor palsy, and a fatal outcome 
within the first 2 years of life. Type 3 (subacute neuro- 
pathic) has a clinical pattern intermediate between types 1 
and 2. We report our results of enzyme replacement therapy 
(ERT) with alglucerase in a patient suffering from type 1 
GD with pulmonary interstitial involvement and severe 
pulmonary hypertension (PHT). 
Case Report 
A 29-year-old Caucasian, not Jewish, woman was first 
diagnosed with Gaucher disease at the age of 9 years, 
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with a clinical picture consisting of a 7-cm hepatomegaly 
and a 12-cm splenomegaly, pancytopenia and bone 
lesions, and after observation of characteristic Gaucher 
disease cells in a bone marrow biopsy and detection of 
enzyme deficiency in peripheral leukocytes (6% of control 
value). DNA analysis showed a N370S/D55 geno- 
type. Thrombocytopenia (platelet counts: 21 000 ,u- ‘), 
anaemia (haemoglobin: 8.1 g dl ~ ‘) and haemorrhagic 
manifestations increased subsequently, and a splenectomy 
was performed at age 19 years, with a subsequent 
correction in blood counts. 
From 1993 (at the age of 24 years), she began to suffer 
from progressive exertional dyspnoea and impaired 
pulmonary function tests, with a reduction of carbon 
monoxide diffusing capacity (DLCO) (Table 1). Chest 
FIG. 1. Chest radiograph showing enlargement of 
pulmonary arteries. 
TABLE 1. Changes in pulmonary function with alglucerase therapy 
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Pretreatment 8 months 18 months 
Increase 
Actual value (“4 Actual value (%I Actual value (%) (%I 
FVC 
FEV, 
FEVJFVC 
FRC 
RV 
TLC 
Hb 
DLCO 
KC0 
PaO, (mmHg) 
PaCO, (mmHg) 
SaO, (%) 
3.81 
2.16 
2.41 
0.78 
4.68 
12.8 
5.10 
1.04 
77.9 
38 
96.5 
(104.5) 
(87.1) 
(72.4) 
(88.4) 
(55.5) 
(91.8) 
(54.1) 
(48.6) 
4.07 
2.88 
2.63 
0.91 
4.88 
13.5 
6.55 
1.18 
84 
31.5 
97.2 
(111.3) 
(90.9) 
(70.7) 
(96.3) 
(64) 
(97) 
(70) 
(55.4) 
4.09 
2.92 
2.80 
1.09 
5.08 
13.2 
6.58 
1.37 
86.4 
37.1 
97.3 
(111.9) 7.4 
(91.5) 4.4 
(71.4) 
(102.9) 14.5 
(75) 19.5 
(99.7) 7.9 
(70.6) 16.5 
(64.8) 16.2 
FVC = forced vital capacity (I); FEV, = forced expiratory volume in 1 s (1); FRC= functional residual capacity (1); RV=residual 
volume (1); TLC=total lung capacity (1); Hbzhaemoglobin (g dl- ‘); D~CO=carbon monoxide diffusing capacity (mmol 
min-’ kPa-‘); KCO= carbon monoxide transfer coefficient (KCO=DLCO/V,). 
radiograph (Fig. 1) showed an enlargement of the 
pulmonary arteries and no parenchymal lesions. A 
transbronchial biopsy obtained by fibrobronchoscopy 
showed an infiltration of lung interstitium by Gaucher cells. 
Enzyme replacement therapy (ERT) was started in 
November 1995 with alglucerase (CeredaseO, Genzyme 
Co., Cambridge, MA) at 2.3 U kg - ’ in i.v. infusion three 
times a week (total dose 32 400 U). The patient had no 
adverse reactions. Eight months later an abdominal ultra- 
sonography showed a 3-cm reduction in her hepatomegaly, 
her dyspnoea improved and an increase in DLCO was noted 
(Table 1). Fifteen months after the onset of treatment, an 
echocardiography was performed, showing a significant 
enlargement of the pulmonary artery (37.9 mm) and right 
cavities, with a pulmonary artery systolic pressure of 
74 mmHg and normal left ventricular function. Six months 
later, a second echocardiography showed no relevant 
changes. The patient refused right cardiac catheteriz- 
ation. As tolerance and clinical response were good, ERT 
treatment was continued at a dose of 15 U kg ~ i every 
2 weeks. 
Discussion 
While pulmonary involvement is relatively common in type 
2 and type 3 GD, it is infrequent in the adult or type 1 form, 
with only a few isolated reports in the medical literature 
(2). In a series of type 1 GD patients, symptomatic 
lung involvement was only found in 3.7% (1). However, 
anatomical descriptions from necropsic studies, including 
the three distinct GD clinical forms, showed pulmonary 
involvement in up to one-third of the patients (3), and that 
42% of the patients in a large series had a significant 
decrease in DLCO (4). 
Most GD patients present with exertion dyspnoea, but 
chest radiographs are usually normal and a diffuse intersti- 
tial pattern is seen only in 17% (4). Respiratory insufficiency 
might be due to intrapulmonary artery-vein anastomosis, 
probably secondary to hepatic involvement, or otherwise to 
lung parenchymal involvement (2). Lung involvement has 
three predominant forms: 1. interstitial infiltration with 
Gaucher cells; 2. Gaucher cells occluding the pulmonary 
capillaries; and 3. Gaucher cells filling the alveolar space, 
producing consolidation (3). 
Another form of pulmonary involvement in GD is pul- 
monary hypertension (PHT): a severe complication associ- 
ated with poor prognosis. Four possible pathophysiological 
mechanisms might account for the development of PTH in 
the individual with GD: 1. perivascular infiltration by 
Gaucher cells with vascular obliteration; 2. plugging of the 
capillaries with Gaucher cells; 3. occlusion of the vascula- 
ture by fat emboli; and 4. the development of PTH in the 
absence of cellular intiltrationZ with a pathological lesion 
similar to that seen in primary PHT (5). 
From 1990 onwards, treatment of GD has been by ERT. 
This treatment may revert symptoms in the majority of 
the patients and substantially improve their quality of life. 
Up to 2000 patients world-wide are being treated with 
alglucerase. Alglucerase is a human placental derivative of 
P-glucocerebrosidase; designed for increasing enzyme cap- 
ture by macrophages, which catalyses glucocerebroside 
hydrolysis (6,7). There has been little experience of ERT in 
pulmonary disease. Only three cases have been described in 
the U.S.A. in which a good response was obtained after 
prolonged therapy (up to 20 months) with i.v. alglucerase 
(8,9). However, all reports agree that this is an important 
indication for the use of ERT (6,7). 
Dawson et ul. (8) described two patients treated with 
alglucerase who developed PHT which was not present 
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prior to treatment. In their article, they discuss the possible 
pathogenetic mechanisms for this complication, and cannot 
exclude an adverse effect of alglucerase. Unfortunately, we 
did not measure initial pulmonary artery pressure in our 
patient, so cannot be sure whether PHT existed before the 
start of ERT. However, a chest radiograph obtained 2 years 
before the start of treatment showed an existing enlarge- 
ment of the pulmonary artery, thus it is likely that PHT did 
exist previously. However, we cannot discard the possibility 
of an influence of ERT on the development of PHT, as 
reported in two patients by Harats et al. (10). 
After 18 months of enzyme replacement theapy, a good 
clinical response has been obtained in our patient, as well as 
an improvement in functional respiratory parameters, 
especially in DLCO. Nevertheless, we cannot rule out the 
possibility that DLCO increase was secondary to the devel- 
opment of PHT, as the latter causes changes in perfusion 
distribution, with an improvement of perfusion in upper 
pulmonary areas. Whilst the pathogenic mechanisms of 
PHT in type 1 GD and the possible role for alglucerase in 
its development cannot be clarified, we consider close 
follow-up to be important in all ERT-treated patients, and 
suggest echocardiography and measurement of pulmonary 
artery pressure and tricuspid gradient prior to the onset 
of alglucerase treatment as general practice in all GD 
patients. 
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